1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Two RFAs were associated with MAGen: RFA-HG-24-004 (Development Sites) and RFA-HG-24-005 (Coordinating Center), both with a July 26, 2024 deadline.
ML/AI Tools to Advance Genomic Translational Research (MAGen) is sponsored by National Institutes of Health (NHGRI). NHGRI aims to establish a research Consortium to explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ML/AI Tools to Advance Genomic Translational Research (MAGen) Funded Programs and Projects ML/AI Tools to Advance Genomic Translational Research (MAGen) Contributing NIH Institutes: National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) Office of Data Science and Strategy (ODSS) The need for increased research to develop tools to translate genomic research findings into clinical applications has been highlighted by NHGRI-convened workshops.
ML/AI techniques have successfully identified novel patterns in non-genomic clinical datasets, receiving FDA approval for ML/AI-enabled medical devices in fields such as radiology, cardiology, and various other disciplines of medicine. Vast amounts of multimodal data are available through advances in FAIR sharing standards and policies, facilitating the potential of using ML/AI approaches in translational genomics.
There is a need to utilize advances in technologies to translate genomic research findings into tools for potential future clinical applications that is we need tools that bridge basic and implementation research referred to in this initiative as, genomics translational research tools developed with disease expert involvement from the design through development and testing.
Maximizing the potential of ML/AI requires thoughtful attention to the ethical, legal, and social implications (ELSI) of its use in genomic medicine and healthcare more broadly. The long-term vision for successful tools would be to test them in clinical implementation settings.
NHGRI aims to establish a research Consortium, ML/AI Tools to Advance Genomic Translational Research (MAGen), to collaboratively explore the feasibility of Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease.
The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools for translational purposes.
Importantly, the Consortium will explore the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine through the establishment of an ELSI Framework for their development, and through implementation of ELSI research projects.
The Consortium will compose of MAGen Development Sites with multi-disciplinary teams to develop the ML/AI tools and the MAGen Coordinating Center which will be responsible for technical, scientific, and administrative coordination activities to support the Consortium research activities including development of Consortium wide plans, coordinated ELSI-informed ML/AI tool development and cross validation, and dissemination of the developed resources.
From the September 18th, 2023, NHGRI Advisory Council Meeting Concept Clearance Presentation Frequently Asked Questions RFA-HG-24-004 : ML/AI Tools to Advance Genomic translational Research (MAGen) – Development Sites (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024| Expiration Date: July 29, 2024 RFA-HG-24-005 : ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/UH3, Clinical Trials Not Allowed) Application Due Dates: July 26, 2024 Expiration Date: July 29, 2024 Related Funding Announcements: Office of Genomic Data Science Division of Genomics and Society Scientific Program Analyst Division of Genome Sciences Division of Neuroscience (DN) Health Data Scientist for AI Ethics Integrated Infrastructure and Emerging Technologies (IIET) Last updated: March 11, 2025
According to the current listing, eligibility includes: City or township governments, county governments, Native American tribal organizations (other than Federally recognized tribal governments), public and state controlled institutions of higher education, public housing a…. Confirm the full requirements in the official notice before applying.
ML/AI Tools to Advance Genomic Translational Research (MAGen) is funded by National Institutes of Health (NHGRI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article